Development of new antidiarrheal medications.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000930:Antidiarrheals / Q000494:pharmacology / Q000627:therapeutic use*; D001834:Body Water / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors; D003967:Diarrhea / Q000188:drug therapy*; D004573:Electrolytes / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007419:Intestinal Secretions / Q000187:drug effects; D009892:Opium / Q000494:pharmacology / Q000627:therapeutic use; D011957:Receptors, Opioid / Q000187:drug effects; D012106:Research; D012964:Sodium / Q000378:metabolism; D013004:Somatostatin / Q000494:pharmacology / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000930:Antidiarrheals; D016861:Cyclooxygenase Inhibitors; D004573:Electrolytes; D011957:Receptors, Opioid; D013004:Somatostatin; D009892:Opium; D012964:Sodium